Nasdaq

Tourmaline Bio, Inc. Confirms Progress in Phase 2 TRANQUILITY Trial and Financial Position Ahead of Key Data Readout

Tourmaline Bio, Inc. announced its first quarter 2025 financial results, highlighting its ongoing Phase 2 TRANQUILITY trial which is set to reveal topline data in the second quarter of 2025. The trial ...
Nasdaq

Tourmaline Bio, Inc. Announces Over-Enrolled Phase 2 TRANQUILITY Trial and Strengthens Cardiovascular Scientific Advisory Board Amid Positive Financial Outlook

Tourmaline Bio, Inc. announced its fourth-quarter and full-year financial results for 2024, highlighting significant progress in its clinical development programs, particularly the Phase 2 TRANQUILITY ...
Seeking Alpha

Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition

The last time I spoke about Tourmaline Bio (TRML) it was with respect to a Seeking Alpha article entitled "Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 Targeting." In this article, I ...
Seeking Alpha

Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive ...

– Rapid, deep, and durable reductions in high-sensitivity C-reactive protein (hs-CRP) through Day 90 achieved across all pacibekitug arms with high statistical significance as compared to placebo (p<0 ...
Hosted on MSN

Tourmaline Bio surges after Novartis $1.4 billion acquisition; analysts see strong fit

Shares of Tourmaline Bio surged in premarket trading on Tuesday after the US-based biotechnology company agreed to be acquired by Swiss pharmaceutical major Novartis for approximately $1.4 billion.